News and Press Releases 2009

RSS Feeds

• December 2, 2009
  Takeda to Continue Strategic Expansion with Operations in Brazil
• November 4, 2009
  Affymax And Takeda Announce Hematide(Tm) Publication In The New England Journal Of Medicine
• November 2, 2009
  Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
• October 30, 2009
  Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated that Hematide(Tm) Increased Hemoglobin in Dialysis Patients
• October 26, 2009
  New Study Results Analyzed the Use of KAPIDEX™ (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
• October 14, 2009
  New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met® (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
• October 1, 2009
  Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
• September 4, 2009
  Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
• August 28, 2009
  Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
• July 22, 2009
  Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl)
• June 26, 2009
  Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
• May 13, 2009
  FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
• March 31, 2009
  Takeda to Create Global Centers of Excellence
• March 12, 2009
  ULORIC® (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
• February 23, 2009
  KAPIDEX™ (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
• February 13, 2009
  FDA Approves ULORIC® (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
• January 30, 2009
  FDA Approves KAPIDEX™ (dexlansoprazole) delayed release capsules for the Treatment of GERD
• January 19, 2009
  Review of Takeda’s Febuxostat New Drug Application Continues Past PDUFA Date